Story thread · 3 reports / 3 sources
Changing fortunes: Is Biotech giant CSL’s $10 billion write-down a comeback story?
smh.com.au · 3h · first report
How the coverage leans
Across 3 sources · syndicated copies counted once
Make no mistake: the home-grown biotechnology company, which for decades allowed Australia serious boasting rights, is still a long way from redemption.
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.